MS is the most common demyelinating disease with an estimated prevalence of 3 in 1000 in the United States. It affects approximately 740,000 individuals in the United States and 2.5 million globally.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Pediatric-onset ...

Increases in sGFAP during BCDT are linked to disability progression in MS, independent of relapse activity. sGFAP is a stronger predictor of disease progression than sNfL, reflecting different ...

Please provide your email address to receive an email when new articles are posted on . WEST PALM BEACH, Fla. — Spinal cord atrophy appeared to predict silent progression in relapse-onset MS, ...

Progression independent of relapse activity (PIRA) is fairly common among patients with multiple sclerosis (MS) and is linked to poorer outcomes in new findings that investigators say should prompt ...

Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving smoldering inflammation and neurodegeneration that drives disability in ...

A pioneering study presented today at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple sclerosis (MS). The breakthrough research has the potential to ...

Please provide your email address to receive an email when new articles are posted on . Progression independent of relapse activity was linked to thinning of certain retinal layers. OCT may be a ...

Blood biomarkers at disease onset may help predict relapse-associated worsening and progression independent of relapse activity (PIRA) in multiple sclerosis (MS), an observational study suggested.